Compare Moderna, Inc. (MRNA) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.15 (market cap $3.80B). The key difference: Moderna, Inc. is far larger — about 20.7× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| MRNA | VNQI | |
|---|---|---|
Market Cap | $78.65B | $3.80B |
Volume | 37,373,437 | 277,049 |
Sector | Health | — |
52-Week High | $203.46 | $50.76 |
52-Week Low | $22.36 | $41.81 |
Typical Hold Time | 59 Days | 95 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
VNQI trades at $41.82, showing minimal daily movement with a 0.02% gain. Technical indicators signal bearish momentum as moving averages show unanimous selling pressure, though oscillators remain neutral. Recent news highlights a significant 45.9% drop in short interest in September 2026, while the fund continues to offer competitive advantages including exposure to international real estate markets across 30+ countries and a higher dividend yield compared to domestic alternatives.
The ETF faces headwinds from global real estate market volatility but maintains structural strengths through diversification and cost efficiency. Key risks include international economic sensitivity and currency fluctuations, while the reduced short interest suggests some investor confidence. Long-term appeal lies in international real estate exposure and income generation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
